Aurobindo Pharma in focus on launch of generic version of Sensipar tablets in US

Published On 2019-07-14 04:45 GMT   |   Update On 2019-07-14 04:45 GMT

Aurobindo Pharma's Cinacalcet Hydrochloride tablets 30mg, 60mg, and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets.


New Delhi: Drug maker Aurobindo Pharma Limited recently announced the launch of Cinacalcet Hydrochloride Tablets (30mg, 60mg, and 90mg) at risk in the US market in accordance with the terms of a settlement agreement with Amgen Inc.


Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg, and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets.


Also Read: Aurobindo Pharma, Dr Reddys, Torrent Pharma, Mylan cannot sell generic Gilenya patented by Novartis


Cinacalcet Hydrochloride tablets are indicated for the treatment of:


• Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKO) on dialysis
• Hypercalcemia in adult patients with parathyroid carcinoma
• Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy


The product had an annual sale of approximately US$ 1,449 million for the twelve months ending May 2019 as per IQVIA.


Also Read: Aurobindo Pharma pulled up by USFDA for repeated CGMP failures

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News